IRIDEX (NASDAQ:IRIX) Coverage Initiated at StockNews.com

Analysts at StockNews.com initiated coverage on shares of IRIDEX (NASDAQ:IRIX) in a research report issued to clients and investors on Monday. The firm set a “hold” rating on the medical equipment provider’s stock.

IRIDEX Stock Performance

IRIDEX stock opened at $1.77 on Monday. The business has a 50 day moving average of $1.65 and a 200-day moving average of $1.96. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.54 and a quick ratio of 0.85. IRIDEX has a 1 year low of $1.27 and a 1 year high of $3.65. The company has a market capitalization of $29.45 million, a P/E ratio of -2.70 and a beta of 0.80.

IRIDEX (NASDAQ:IRIX) last announced its quarterly earnings results on Tuesday, November 12th. The medical equipment provider reported ($0.12) earnings per share (EPS) for the quarter. The business had revenue of $11.58 million during the quarter. IRIDEX had a negative net margin of 22.79% and a negative return on equity of 192.95%. During the same period in the prior year, the business posted ($0.11) EPS.

About IRIDEX

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.